PureTech Health plc announced the formation of its Clinical Advisory Board for idiopathic pulmonary fibrosis (IPF) and other progressive fibrosing interstitial lung diseases (PF-ILDs). Members of the Clinical Advisory Board include: Bill Bradford, M.D., Ph.D., is a biopharma advisor with broad expertise in drug development. Vincent Cottin, M.D., is a Professor of Respiratory Medicine at Université Claude Bernard Lyon and Coordinator of the National Coordinating Reference Center for Rare Pulmonary Diseases at Louis Pradel Hospital, Hospices Civils de Lyon, Lyon, France. Kevin Flaherty, M.D., is a Professor at the University of Michigan specializing in IPF and other ILDs. Toby Maher, M.D., Ph.D., is a Professor of Clinical Medicine and Director of Interstitial Lung Disease at Keck School of Medicine of the University of Southern California. Paul Noble, M.D., is Chair of the Department of Medicine at Cedars-Sinai Medical Center and a noted researcher in lung inflammation and fibrosis. Marlies Wijsenbeek, M.D., Ph.D., is a pulmonary physician at the Erasmus Medical Center.